Avapritinib

Major

Avapritinib Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Avapritinib Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Avapritinib Paritaprevir Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Pexidartinib Turalio Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Phenobarbital Fidoquel Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Phenytoin Dilantin Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Avapritinib Posaconazole Noxafil Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Primidone Mysoline Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Avapritinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Avapritinib Repotrectinib Augtyro Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Ribociclib Kisqali Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Rifabutin Mycobutin Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Rifampin Rifadin Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Avapritinib Ritonavir Norvir Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Avapritinib Saquinavir Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Schisandra Sphenanthera Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Sotorasib Lumakras Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib St John's Wort Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Suzetrigine Journavx Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Avapritinib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Avapritinib Telaprevir Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Telithromycin Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Telotristat Ethyl Xermelo Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Thioridazine Reduced avapritinib exposure and reduced efficacy of avapritinib Details Avapritinib Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Avapritinib Troleandomycin Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Tucatinib Tukysa Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Verapamil Calan Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Voriconazole Vfend Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Voxelotor Oxbryta Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Ketoconazole Topical Extina® Foam Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Avapritinib Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Avapritinib Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Avapritinib Letermovir Injection Prevymis Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Avapritinib Nafcillin Injection Unipen® Injection Reduced avapritinib exposure and reduced efficacy of avapritinib Details

Moderate

Avapritinib Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details